

Message Text

UNCLASSIFIED

PAGE 01 OTTAWA 01282 150001Z
ACTION ABF-01

INFO OCT-01 EUR-12 ISO-00 L-03 DEAE-00 SNM-05 SS-15

A-01 /038 W

-----110125 150744Z /10

R 142359Z MAR 78
FM AMEMBASSY OTTAWA
TO SECSTATE WASHDC 6644

UNCLAS OTTAWA 01282

E.O. 11652: N/A
TAGS: AGAO, ECSV
SUBJECT: GAO REVIEW: "NEW DRUG DEVELOPMENT AND APPROVAL
PROCESS"

REF: STATE 54538 AND OTTAWA 1213

1. APPOINTMENT FOR GAO TEAM WITH DR. A.B. MORRISON,
ASSISTANT DEPUTY MINISTER, HEALTH PROTECTION BRANCH, HEALTH
AND WELFARE CANADA, SCHEDULED FOR 9:00 A.M., TUESDAY, APRIL
4, FOLLOWED BY MEETING AT APPROXIMATELY 9:45 A.M. WITH
DR. R.C.B. GRAHAM, ASSISTANT DIRECTOR, BUREAU OF DRUGS.

2. DR. IAN HENDERSON WITH WHOM TEAM REQUESTED APPOINTMENT
WAS CHAIRMAN OF THE CANADIAN MEDICAL ASSOCIATION (CMA)
SUBCOMMITTEE ON PHARMACOTHERAPY BUT RECENTLY ACCEPTED
APPOINTMENT WITH HEALTH AND WELFARE AS DIRECTOR OF BUREAU
OF DRUGS (NOW DR. GRAHAM'S BOSS). REPRESENTATIVE OF CMA,
WITH WHOM WE DISCUSSED REQUEST, INDICATED DR. HENDERSON'S
SUCCESSOR AS CHAIRMAN OF THE SUBCOMMITTEE ON PHARMOCO-
THERAPY MIGHT NOT BE APPROPRIATE PERSON FOR PRESENT
DISCUSSION.

3. DR. GRAHAM SAID REPRESENTATIVE OF BUREAU OF DRUG
SURVEILLANCE WILL BE AVAILABLE BUT AT THE MOMENT HE COULD
NOT PROVIDE INDIVIDUAL'S NAME.

UNCLASSIFIED

UNCLASSIFIED

PAGE 02 OTTAWA 01282 150001Z

4. PLEASE ADVISE WHETHER YOU WISH EMBASSY TO MAKE ADDITIONAL
APPOINTMENTS BEFORE TEAM'S ARRIVAL. CMA SUGGESTED
REPRESENTATIVE OF THE MEDICAL SECTION OF THE PHARMACEUTICAL
MANUFACTURERS ASSOCIATION OF CANADA MIGHT BE APPROPRIATE.
CHAIRMAN OF MEDICAL SECTION IS DR. R. WATERS, MEDICAL
DIRECTOR, FISONS (CANADA) LTD., 26 PRINCE ANDREW PLACE,

DON MILLS, ONTARIO; SECRETARY IS DR. K. CARTWRIGHT, HEAD
OF CLINICAL INVENTORY, CIBA-GEIGY CANADA LIMITED,
205 BOUCHARD, DORVAL, QUEBEC.

5. RESERVATIONS FOR FOUR NIGHTS BEGINNING APRIL 3
CONFIRMED LORD ELGIN HOTEL FOR HERMANN, GRANT, HUDAQ,
VIEREGGE AND SMITH. ENDERS

UNCLASSIFIED

NNN

Message Attributes

Automatic Decaptoning: X
Capture Date: 01 jan 1994
Channel Indicators: n/a
Current Classification: UNCLASSIFIED
Concepts: DRUGS, MEETINGS, PROGRAMS (PROJECTS)
Control Number: n/a
Copy: SINGLE
Draft Date: 14 mar 1978
Decapton Date: 01 jan 1960
Decapton Note:
Disposition Action: n/a
Disposition Approved on Date:
Disposition Case Number: n/a
Disposition Comment:
Disposition Date: 01 jan 1960
Disposition Event:
Disposition History: n/a
Disposition Reason:
Disposition Remarks:
Document Number: 1978OTTAWA01282
Document Source: CORE
Document Unique ID: 00
Drafter: n/a
Enclosure: n/a
Executive Order: N/A
Errors: N/A
Expiration:
Film Number: D780114-1018
Format: TEL
From: OTTAWA
Handling Restrictions: n/a
Image Path:
ISecure: 1
Legacy Key: link1978/newtext/t19780371/aaaaciat.tel
Line Count: 69
Litigation Code IDs:
Litigation Codes:
Litigation History:
Locator: TEXT ON-LINE, ON MICROFILM
Message ID: b2e3f5c7-c288-dd11-92da-001cc4696bcc
Office: ACTION ABF
Original Classification: UNCLASSIFIED
Original Handling Restrictions: n/a
Original Previous Classification: n/a
Original Previous Handling Restrictions: n/a
Page Count: 2
Previous Channel Indicators: n/a
Previous Classification: n/a
Previous Handling Restrictions: n/a
Reference: 78 STATE 54538, 78 OTTAWA 1213
Retention: 0
Review Action: RELEASED, APPROVED
Review Content Flags:
Review Date: 15 mar 2005
Review Event:
Review Exemptions: n/a
Review Media Identifier:
Review Release Date: n/a
Review Release Event: n/a
Review Transfer Date:
Review Withdrawn Fields: n/a
SAS ID: 3340579
Secure: OPEN
Status: NATIVE
Subject: GAO REVIEW: "NEW DRUG DEVELOPMENT AND APPROVAL PROCESS"
TAGS: AGAO, ECRM, US, CA, (MORRISON, A B), (GRAHAM, R C B)
To: STATE
Type: TE
vdkgvgwkey: odbc://SAS/SAS.dbo.SAS_Docs/b2e3f5c7-c288-dd11-92da-001cc4696bcc
Review Markings:
Sheryl P. Walter
Declassified/Released
US Department of State
EO Systematic Review
20 Mar 2014
Markings: Sheryl P. Walter Declassified/Released US Department of State EO Systematic Review 20 Mar 2014